MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma
- 1 April 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4) , 666-672
- https://doi.org/10.1373/clinchem.2006.079327
Abstract
Background: Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARK™, a quantitative assay for SMRP.Keywords
This publication has 15 references indexed in Scilit:
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Advances in the diagnosis, evaluation, and management of malignant pleural mesotheliomaRespirology, 2005
- Characterization of human mesothelin transcripts in ovarian and pancreatic cancerBMC Cancer, 2004
- Pathogenesis of Malignant MesotheliomaClinical Lung Cancer, 2004
- Mesothelin-family proteins and diagnosis of mesotheliomaThe Lancet, 2003
- Application of Mesothelin Immunostaining in Tumor DiagnosisThe American Journal of Surgical Pathology, 2003
- The pathogenesis of mesotheliomaSeminars in Oncology, 2002
- Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaProceedings of the National Academy of Sciences, 1999
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- The Pathogenesis of Asbestos-Associated DiseasesNew England Journal of Medicine, 1982